Loading
Paper cited by two bottleneck pages, indexed on Europe PMC as PubMed record 27913228 and published in Journal of Thoracic Oncology; the citing pages link this DOI, which is how the record was matched.
Introduction: The Blueprint Programmed Death Ligand 1 (PD-L1) Immunohistochemistry (IHC) Assay Comparison Project is an industrial-academic collaborative partnership to provide information on the analytical and clinical comparability of four PD-L1 IHC assays used in clinical trials.
Methods: A total of 39 NSCLC tumors were stained with four PD-L1 IHC assays (22C3, 28-8, SP142, and SP263), as used in the clinical trials. Three experts in interpreting their respective assays independently evaluated the percentages of tumor and immune cells staining positive at any intensity. Clinical diagnostic performance was assessed through comparisons of patient classification above and below a selected expression cutoff and by agreement using various combinations of assays and cutoffs.
Results: Analytical comparison demonstrated that the percentage of PD-L1-stained tumor cells was comparable when the 22C3, 28-8, and SP263 assays were used, whereas the SP142 assay exhibited fewer stained tumor cells overall. The variability of immune cell staining across the four assays appears to be higher than for tumor cell staining. Of the 38 cases, 19 (50.0%) were classified above and five (13%) were classified below the selected cutoffs of all assays. For 14 of the 38 cases (37%), a different PD-L1 classification would be made depending on which assay/scoring system was used.
Conclusions: The Blueprint PD-L1 IHC Assay Comparison Project revealed that three of the four assays were closely aligned on tumor cell staining whereas the fourth showed consistently fewer tumor cells stained. All of the assays demonstrated immune cell staining, but with greater variability than with tumor cell staining. By comparing assays and cutoffs, the study indicated that despite similar analytical performance of PD-L1 expression for three assays, interchanging assays and cutoffs would lead to "misclassification" of PD-L1 status for some patients. More data are required to inform on the use of alternative staining assays upon which to read different specific therapy-related PD-L1 cutoffs.
Indexed on Europe PMC as PubMed record 27913228 (DOI 10.1016/j.jtho.2016.11.2228). Matched by DOI alone: two bottleneck pages cite this DOI among their external links (the pages are listed under Related), and this page was written so that the citation resolves inside OnCo. No figure has been checked by an editor.
Two bottleneck pages on OnCo cite this paper by its DOI; this record gives the citation a page of its own so a reader can follow it without leaving OnCo. Read the abstract above alongside the citing pages listed under Related; the record was created automatically from the Europe PMC entry and its figures have not been checked by hand.
Shares PD-L1 TC score (tumour-cell score, SP263 and 28-8), PD-L1 IC score (immune-cell score, SP142), PD-L1 TPS (tumour proportion score), Journal of Thoracic Oncology.
Shares PD-L1 TC score (tumour-cell score, SP263 and 28-8), PD-L1 IC score (immune-cell score, SP142), PD-L1 TPS (tumour proportion score), Immunohistochemistry (IHC).
Shares PD-L1 TC score (tumour-cell score, SP263 and 28-8), Immunohistochemistry (IHC), PD-1 / PD-L1 immune checkpoint & T-cell activation, Histopathology & immunohistochemistry.
Shares PD-L1 TC score (tumour-cell score, SP263 and 28-8), PD-L1 TPS (tumour proportion score), Immunohistochemistry (IHC), Histopathology & immunohistochemistry.
Shares PD-L1 TC score (tumour-cell score, SP263 and 28-8), PD-L1 IC score (immune-cell score, SP142), Immunohistochemistry (IHC), No one can predict who responds to immunotherapy.
Shares PD-L1 TPS (tumour proportion score), Immunohistochemistry (IHC), PD-L1.
Shares PD-L1 TPS (tumour proportion score), Immunohistochemistry (IHC), PD-L1.
Shares PD-L1 TPS (tumour proportion score), Immunohistochemistry (IHC), PD-1 / PD-L1 immune checkpoint & T-cell activation, Histopathology & immunohistochemistry.